BusinessBioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia ABy Nasdaq OMXMar 1, 2016, 10:43 PM UTC
BusinessBioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease PatientsBy Nasdaq OMXFeb 29, 2016, 1:30 PM UTC
BusinessBioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 PosterBy Nasdaq OMXFeb 29, 2016, 1:25 PM UTC
BusinessBioMarin Announces Fourth Quarter and Full Year 2015 Financial ResultsBy Nasdaq OMXFeb 25, 2016, 9:02 PM UTC
BusinessBioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ETBy Nasdaq OMXJan 28, 2016, 1:30 PM UTC
BusinessFDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingBy Nasdaq OMXJan 14, 2016, 1:30 PM UTC
BusinessBioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare ConferenceBy Nasdaq OMXJan 11, 2016, 4:30 PM UTC
